Copyright
©The Author(s) 2019.
Figure 1 Final treatment outcome (n = 34).
MS-LCH: Multisystem Langerhans cell histiocytosis; SS-LCH: Single-system Langerhans cell histiocytosis; NAD: Nonactive disease; ADR: Active disease regressive; ADS: Active disease stable; PD: Progression disease.
- Citation: Mauro E, Stefani PM, Gherlinzoni F. Adult Langerhans cell histiocytosis and immunomodulatory drugs: Review and analysis of thirty-four case reports. World J Hematol 2019; 8(1): 1-9
- URL: https://www.wjgnet.com/2218-6204/full/v8/i1/1.htm
- DOI: https://dx.doi.org/10.5315/wjh.v8.i1.1